A composition of zinc salts of carboxylic acids. The carboxylic acids of the zinc salts include 0.5 to 6.0 mass % of a component (A), 0.05 to 1.2 mass % of a component (B) and 88.0 to 98.0 mass % of a component (C) described below. A ratio [(A)/(B)] of a mass of the component (A) with respect to a mass of the component (B) is 99/1 to 75/25, where (A) is a straight chain and saturated carboxylic acid having a carbon number of 12 to 22; (B) is a strait chain and unsaturated carboxylic acid having one unsaturated bond and a carbon number of 18, said unsaturated bond comprising a trans-form double bond; and (C) is a straight-chain and unsaturated carboxylic acid having one unsaturated bond and a carbon number of 18, said unsaturated bond comprising a cis-form double bond.

A green chemistry hydrometallurgical process for recovering one or more metals from a metal-containing material includes leaching the metal-containing material with formic acid, obtaining a leachate comprising the one or more metals as one or more metal formates, and precipitating at least one of the one or more metal formates. The metal-containing material may be a lithium-ion battery cathode material, resulting in Li formate remaining in solution and precipitation of salts including one or more of Ni, Co, and Mn formates. Steps may include filtration of the leachate, sulphurization of retained metal formate salts to produce metal sulphate salts, purification of filtered leachate by adding lithium carbonate and filtering, dewatering of the purified leachate, and thermal decomposition of resulting lithium salts to produce battery grade lithium carbonate. Carbon dioxide, water, and formic acid may be recovered and reused, without liquid or solid waste produced.

A green chemistry hydrometallurgical process for recovering one or more metals from a metal-containing material includes leaching the metal-containing material with formic acid, obtaining a leachate comprising the one or more metals as one or more metal formates, and precipitating at least one of the one or more metal formates. The metal-containing material may be a lithium-ion battery cathode material, resulting in Li formate remaining in solution and precipitation of salts including one or more of Ni, Co, and Mn formates. Steps may include filtration of the leachate, sulphurization of retained metal formate salts to produce metal sulphate salts, purification of filtered leachate by adding lithium carbonate and filtering, dewatering of the purified leachate, and thermal decomposition of resulting lithium salts to produce battery grade lithium carbonate. Carbon dioxide, water, and formic acid may be recovered and reused, without liquid or solid waste produced.

Disclosed is a novel process for the synthesis of tofacitinib citrate on an industrial scale with high yields and purity starting with cis-(1-benzyl-4-methyl-piperidin-3-yl)methylamine bis-hydrochloride racemate (intermediate VIII), which comprises: 1. Condensation between intermediates VII and VIII to give intermediate VI 2. Hydrogenation of intermediate VI to give intermediate V 3. Resolution of intermediate V to give intermediate IV with enantiomeric purity >99% 4. Release of intermediate IV in a basic medium to give intermediate III 5. N-acylation reaction of intermediate III to give II (tofacitinib) 6. Salification of intermediate II to give tofacitinib monocitrate (I) ##STR00001## ##STR00002##

Disclosed is a novel process for the synthesis of tofacitinib citrate on an industrial scale with high yields and purity starting with cis-(1-benzyl-4-methyl-piperidin-3-yl)methylamine bis-hydrochloride racemate (intermediate VIII), which comprises: 1. Condensation between intermediates VII and VIII to give intermediate VI 2. Hydrogenation of intermediate VI to give intermediate V 3. Resolution of intermediate V to give intermediate IV with enantiomeric purity >99% 4. Release of intermediate IV in a basic medium to give intermediate III 5. N-acylation reaction of intermediate III to give II (tofacitinib) 6. Salification of intermediate II to give tofacitinib monocitrate (I) ##STR00001## ##STR00002##

There is provided individual polymorphic forms of treprostinil and pharmaceutical formulations comprising the same, methods of making and using the same.

There is provided individual polymorphic forms of treprostinil and pharmaceutical formulations comprising the same, methods of making and using the same.

The present invention refers to new solid forms of Enclomiphene citrate and Enclomiphene base, processes for preparing thereof and uses.

The present invention refers to new solid forms of Enclomiphene citrate and Enclomiphene base, processes for preparing thereof and uses.

Provided is a metal salt of an alicyclic dicarboxylic acid with excellent dispersibility in polyolefin resins, and excellent crystallinity improving effect that is essential as a crystal nucleating agent for polyolefin resins, regardless of processing conditions. A method is also provided for producing the metal salt of an alicyclic dicarboxylic acid; a crystal nucleating agent containing the metal salt of an alicyclic dicarboxylic acid; a crystal nucleating agent composition for polyolefin resins containing the crystal nucleating agent and a fatty acid metal salt; a polyolefin resin composition containing the crystal nucleating agent; and a polyolefin resin molded article obtained using the polyolefin resin composition. Provided is a metal salt of an alicyclic dicarboxylic acid in which the alicyclic dicarboxylic acid is an alkyl substituent-containing cyclohexane-1,2-dicarboxylic acid, and the metal salt is a calcium salt, a hydroxyaluminum salt, a disodium salt, or a dilithium salt.